

**Study Number:** MOG003B

**Test Type:** MOG

**Route:** Dosing in Feed

**Species/Strain:** Rat/Sprague-Dawley

**C Number:**

**Study Gender:**

**PWG Approval Date**

**PA41: Clinical Chemistry Summary**

**Test Compound:** 2-Ethylhexyl p-Methoxycinnamate

**CAS Number:** 5466-77-3

MOG003B

Both

See web page for date of PWG Approval

**Date Report Requested:** 01/14/2020

**Time Report Requested:** 11:04:56

**Lab:** RTI

**Study Number:** MOG003B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** 2-Ethylhexyl p-Methoxycinnamate  
**CAS Number:** 5466-77-3

**Date Report Requested:** 01/14/2020  
**Time Report Requested:** 11:04:56  
**Lab:** RTI

**F1 Male: Subchronic Male**

	Phase Day	Treatment Groups (ppm)			
		0	1000	3000	6000
Urea Nitrogen (mg/dL)	PND 110 - 112	22.5 ± 0.5 (10)	22.3 ± 0.8 (10)	22.3 ± 0.9 (10)	22.3 ± 0.5 (10)
Percent of Control			99.1	99.1	99.1
Creatinine (mg/dL)	PND 110 - 112	0.57 ± 0.02 (10)	0.53 ± 0.02 (10)	0.56 ± 0.02 (10)	0.55 ± 0.02 (10)
Percent of Control			93.0	98.2	96.5
Glucose (mg/dL)	PND 110 - 112	442.0 ± 25.0 (10)	460.6 ± 27.7 (10)	454.1 ± 35.1 (10)	444.6 ± 37.6 (10)
Percent of Control			104.2	102.7	100.6
Total Protein (g/dL)	PND 110 - 112	6.94 ± 0.08 (10)	6.95 ± 0.05 (10)	6.90 ± 0.06 (10)	6.88 ± 0.05 (10)
Percent of Control			100.1	99.4	99.1
Albumin (g/dL)	PND 110 - 112	3.51 ± 0.04 (10)	3.45 ± 0.04 (10)	3.51 ± 0.05 (10)	3.49 ± 0.04 (10)
Percent of Control			98.3	100.0	99.4
Cholesterol (mg/dL)	PND 110 - 112	98.6 ± 4.9 (10)	106.4 ± 4.4 (10)	110.4 ± 5.5 (10)	104.9 ± 6.8 (10)
Percent of Control			107.9	112.0	106.4
Triglyceride (mg/dL)	PND 110 - 112	169.4 ± 24.2 (10)	179.0 ± 20.7 (10)	171.8 ± 20.0 (10)	149.7 ± 15.0 (10)
Percent of Control			105.7	101.4	88.4
Alanine Aminotransferase (U/L)	PND 110 - 112	95.2 ± 9.9 (10)	92.1 ± 6.0 (10)	187.1 ± 85.3 (10)	92.4 ± 6.0 (10)
Percent of Control			96.7	196.5	97.1
Alkaline Phosphatase (U/L)	PND 110 - 112	219.9 ± 9.4 (10)	205.5 ± 15.1 (10)	226.7 ± 12.3 (10)	229.3 ± 6.2 (10)
Percent of Control			93.5	103.1	104.3
Creatine Kinase (U/L)	PND 110 - 112	204.6 ± 49.4 (10)	160.1 ± 13.7 (10)	139.4 ± 17.9 (10)	226.2 ± 52.1 (10)
Percent of Control			78.3	68.1	110.6
Sorbitol Dehydrogenase (U/L)	PND 110 - 112	28.0 ± 1.9 (10)	28.9 ± 1.8 (10)	43.5 ± 15.3 (10)	25.9 ± 1.6 (10)
Percent of Control			103.5	155.5	92.7

**Study Number:** MOG003B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** 2-Ethylhexyl p-Methoxycinnamate  
**CAS Number:** 5466-77-3

**Date Report Requested:** 01/14/2020  
**Time Report Requested:** 11:04:56  
**Lab:** RTI

---

**F1 Male: Subchronic Male**

---

	Phase Day	Treatment Groups (ppm)			
		0	1000	3000	6000
Bile salt/acids (umol/L)	PND 110 - 112	29.7 ± 3.5 (10)	21.0 ± 2.7 (10)	19.5 ± 2.5 (10)	24.5 ± 3.1 (10)
Percent of Control			70.7	65.6	82.6

Study Number: MOG003B

Test Type: MOG

Route: Dosing in Feed

Species/Strain: Rat/Sprague-Dawley

PA41: Clinical Chemistry Summary

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

Date Report Requested: 01/14/2020

Time Report Requested: 11:04:56

Lab: RTI

F1 Female: Subchronic Female

	Phase Day	Treatment Groups (ppm)			
		0	1000	3000	6000
Urea Nitrogen (mg/dL)	PND 111 - 113	22.7 ± 0.9 (10)	22.2 ± 0.9 (10)	21.5 ± 0.6 (10)	22.3 ± 1.1 (10)
Percent of Control			97.8	94.7	98.2
Creatinine (mg/dL)	PND 111 - 113	0.55 ± 0.02 (10)	0.54 ± 0.02 (10)	0.58 ± 0.01 (10)	0.56 ± 0.02 (10)
Percent of Control			98.2	105.5	101.8
Glucose (mg/dL)	PND 111 - 113	368.1 ± 9.5 (10)	365.0 ± 18.8 (10)	383.6 ± 24.8 (10)	338.4 ± 16.5 (10)
Percent of Control			99.2	104.2	91.9
Total Protein (g/dL)	PND 111 - 113	6.65 ± 0.08 (10)	6.61 ± 0.09 (10)	6.72 ± 0.10 (10)	6.68 ± 0.09 (10)
Percent of Control			99.4	101.1	100.5
Albumin (g/dL)	PND 111 - 113	3.56 ± 0.04 (10)	3.50 ± 0.05 (10)	3.61 ± 0.05 (10)	3.61 ± 0.05 (10)
Percent of Control			98.3	101.4	101.4
Cholesterol (mg/dL)	PND 111 - 113	104.9 ± 3.5 (10)	101.3 ± 4.1 (10)	98.4 ± 9.1 (10)	97.3 ± 4.6 (10)
Percent of Control			96.6	93.8	92.8
Triglyceride (mg/dL)	PND 111 - 113	95.2 ± 8.2 (10)	105.8 ± 10.7 (10)	90.8 ± 15.4 (10)	89.9 ± 13.2 (10)
Percent of Control			111.1	95.4	94.4
Alanine Aminotransferase (U/L)	PND 111 - 113	93.5 ± 3.6 (10) **	80.9 ± 8.5 (10)	78.9 ± 10.6 (10) *	70.2 ± 4.9 (10) **
Percent of Control			86.5	84.4	75.1
Alkaline Phosphatase (U/L)	PND 111 - 113	218.8 ± 14.1 (10)	203.1 ± 13.8 (10)	199.1 ± 9.3 (10)	198.3 ± 9.6 (10)
Percent of Control			92.8	91.0	90.6
Creatine Kinase (U/L)	PND 111 - 113	150.5 ± 17.4 (10)	152.8 ± 19.4 (10)	155.8 ± 39.8 (10)	133.9 ± 16.1 (10)
Percent of Control			101.5	103.5	89.0
Sorbitol Dehydrogenase (U/L)	PND 111 - 113	27.4 ± 2.3 (10)	26.3 ± 2.8 (10)	35.1 ± 11.0 (10)	25.6 ± 1.5 (10)
Percent of Control			96.2	128.3	93.3

**Study Number:** MOG003B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** 2-Ethylhexyl p-Methoxycinnamate  
**CAS Number:** 5466-77-3

**Date Report Requested:** 01/14/2020  
**Time Report Requested:** 11:04:56  
**Lab:** RTI

---

**F1 Female: Subchronic Female**

---

	Phase Day	Treatment Groups (ppm)			
		0	1000	3000	6000
Bile salt/acids (umol/L)	PND 111 - 113	28.0 ± 5.5 (10)	28.7 ± 4.8 (10)	31.2 ± 9.5 (10)	28.4 ± 4.8 (10)
Percent of Control			102.5	111.5	101.3

**Study Number:** MOG003B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** 2-Ethylhexyl p-Methoxycinnamate  
**CAS Number:** 5466-77-3

**Date Report Requested:** 01/14/2020  
**Time Report Requested:** 11:04:56  
**Lab:** RTI

#### LEGEND

---

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

PND - Postnatal Day, adults post-weaning

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

**\*\* END OF REPORT \*\***